CD200

Across TCGA pan-cancer cohorts, CD200 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CD200 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CD200 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD200 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

UCEC, LUAD, and CCRCC are the cancer types where CD200 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Quartile	All	0.707	0.961	.006	14	view →
LUAD	OS	Quartile	II,III,IV	0.778	1.000	.009	11	view →
CCRCC	OS	Median	All	1.000	0.657	.005	11	view →
COAD	DFS	Median	II,III,IV	0.807	1.000	.048	6	view →
PDAC	OS	Tertile	III,IV	0.545	0.948	.016	6	view →
GBM	DFS	Median	All	0.799	0.690	.019	4	view →
LSCC	DFS	Tertile	II,III,IV	0.849	1.000	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CD200–UCEC (DFS)

Open the UCEC breakdown →